Short stories

Startups raise funds, Houston biz contest opens apps, and more innovation news

Texans see need for telemedicine amid the pandemic, Liftoff Houston has launched applications, ChipMonk Bakery is growing, and more of the latest Houston innovation news. Getty Images

From health-conscious cookies reaching fundraising goals to a Houston-wide business competition, the Bayou City's innovation news is pretty diverse.

In InnovationMap's latest roundup of startup and tech short stories, there's everything from telemedicine, fundraising, and more.

Houston baking startup raises money after finding its new home

ChipMonk Baking Company, a consumer packaged goods startup focused on healthy dessert options, has met its goal of $150,000. Photo courtesy of ChipMonk

Houston-based ChipMonk Baking Company, which recently found a new home in a new dedicated production facility, has reached its goal on its investment round on NextSeed.

ChipMonk, which was founded last year to create sweets that use sweeteners monk fruit and allulose for health-conscious consumers, will soon operate in a 2,300-square-foot space at 3042 Antoine Dr. The space is strictly for baking, storage, etc. and will not have a storefront.

Co-founders Jose Hernandez and David Downing have seen a spike in demand since the start of the pandemic, which increased the need to upgrade from shared kitchen space.

"The stay-at-home environment has encouraged many people to think more about their health and to start cooking and baking more at home. We've been able to offer a delicious option that fits perfectly in this growing trend," says Downing, who also serves as CEO.

ChipMonk's lease begins next month, and, to fund its growth plans, the company launched a its campaign on NextSeed. In just a couple weeks, the startup met its fundraising goal of $150,000.

Cancer nonprofit moves into new space

The Rose has a new facility to better serve patients. Photos courtesy of The Rose

The Rose, a Houston-based breast cancer nonprofit that provides medical services to 40,000 patients annually, has moved into its new space at 6575 West Loop South, suite 275, in May.

"We know this location will allow us to better serve our community," says Dorothy Gibbons, co-founder and CEO of The Rose, in a news release. "During this time of the pandemic, we've added so many safety precautions and will continue to space appointments to allow social distancing. Most of all we want our patients to feel safe and welcome from the moment they walk through our door."

Amid the COVID-19 pandemic, data reports have shown a drop in routine health care, like cervical and breast cancer screenings. Gibbons says the drop in these appointments is concerning and those who postpone routine screening or diagnostic testing could be at risk for developing later stage breast cancer.

"Our message to our patients is breast cancer is not going to wait until this pandemic is over; neither should you. With the projected increase in uninsured women, due to so many job losses, The Rose has to be ready to serve. Now more than ever, we depend on our insured patients to help cover the care for uninsured patients," she says.

Houston business competition opens applications

Small businesses in Houston have until August 10 to apply for the annual Liftoff Houston competition. Photo via liftoffhouston.smapply.org

The city of houston's annual business plan competition, Liftoff Houston, has opened applications. The program, which is sponsored by Capital One Bank, is looking for companies and will award winners in three categories: Product, service, and innovation

Each business that wins will receive a $10,000 cash prize. The competition is focused on early stage startups with revenue less than $10,000 and must have only been in business for less than a year. The companies also must be based in Houston.

Applicants can submit their information online to be considered for the contest. The deadline to apply is August 10.

TMCx company closes $1.53 million seed round

Manatee

Manatee has raised funds for its digital therapy platform. Photo via getmanatee.com

Manatee, a health tech startup based in Denver that was a member of this year's TMCx cohort, has announced it closed its seed funding round at $1.53 million. The company, which provides digital solutions to therapy for children, closed the round at the end of June.

Michigan-based Grand Ventures led the raise and invested alongside The American Family Insurance Institute (AmFam), Telosity, SpringTime Ventures, and notable health care entrepreneurs, Danish Munir, Luke Leninger, and Johnathan Weiner, according to information emailed by Manatee representative.

"Manatee was the first solution we found that really understood kids and their unique needs," says Christopher Neuharth, executive director of digital health and experience at Children's Wisconsin. "They got the dynamics between the child, parent, and therapist – and how to influence behavior change."

Accenture study finds COVID-19 has been a gamechanger for telemedicine

Houston medical organizations pivot to telemedicine and remote care amid COVID-19 crisis

An Accenture study found that most Texans are seeking telehealth amid the pandemic. Getty Images

According to a recent study from Accenture, 89 percent of Texas consumers want telehealth options — and the COVID-19 pandemic deserves the credit for the increased interest.

According to a press release from the company, the research found that:

  • One-fourth of Texans surveyed said they first learned about virtual health care following the outbreak of COVID-19.
  • The number of Texans who said they know a little or a lot about virtual health care increased 25 percent following the outbreak.
  • Approximately nine in 10 Texans surveyed after the pandemic began believe that virtual care options should be available to everyone.

The widespread stay-at-home orders exposed Texans to virtual health care and left a positive impression on receiving care remotely. For instance:

  • An estimated 4.5 million state residents began using virtual health care services since the onset of the pandemic.
  • Nearly half (45 percent) of Texans said they trust a virtual health visit as much as or more than an in-person visit—a 15 percent uptick from the pre-pandemic period.
  • Six out of seven remote-care patients (86 percent) who have continued to use virtual care options during the pandemic said their experience after the start of the COVID-19 outbreak was better or the same as before, and three-quarters (76 percent) said their wait time was shorter or the same.

"A lot of Texans got a taste for what it's like to see their physicians and specialists from the safety and comfort of their home," says Mark Olney, a managing director in Accenture's health practice and the study's lead author. "Now patients are eager to get more of that access, convenience and time savings."

Trending News

Building Houston

 
 

The Texas Medical Center Innovation Factory has named the 16 companies making up the inaugural cohort in the Innovate UK Global Incubator Programme. Photo via tmc.edu

Sixteen digital health and medical device startups founded in the United Kingdom have been selected for a customized accelerator at the Texas Medical Center's Innovation Factory.

In partnership with Innovate UK, TMCi created the Innovate UK Global Incubator Programme, a new accelerator that supports UK businesses as they build their United States go-to-market plan. The program builds the BioBridge relationship between TMC and the UK that was originally established five years ago.

“The TMC UK BioBridge program was launched with the UK Department for Business and Trade in 2018 to serve as a gateway for advancing life sciences and foster innovation and research between our two countries," says Ashley McPhail, chief external affairs and administration officer for TMC, in a news release. "We saw an opportunity to work with Innovate UK to develop a larger program with the UK after the success of the 11 companies that previously participated in our health tech accelerator."

The 16 companies will participate in the program from June to November. The cohort is expected to arrive in Houston on June 5 and have access to TMCi's facilities, network of mentors and potential clients, funding, potential customers, and curated programing — all while being a unique entry point into the US. The new offering joins three other globally recognized curriculums: Biodesign, Accelerator for Cancer Therapeutics, and Health Tech.

“TMCi nurtures long-term growth, development, and competitiveness to increase startups chances of success and global expansion," says Emily Reiser, associate director of TMC Innovation. "By bringing their novel technologies and exposing them to a curated selection of TMC’s expert network, startups receive support and evaluation to build, scale, and expand in the US market."

Two of the cohort's specialties include cardiovascular and oncology — two of TMC's strongest areas of expertise — with solutions ranging from surgical devices to AI-enabled risk stratification and hospital efficiency.

Innovate UK is the country's national innovation agency dedicated to supporting business-led innovation in all sectors.

“The United Kingdom is fully committed to improving global healthcare through scientific collaboration," says His Majesty’s Consul General in Texas Richard Hyde in the release. "Through the expansion of the TMC UK BioBridge and in partnership with Innovate UK, this programme will help to expose the brightest and best British companies to the world’s largest medical city. Our companies will collaborate and grow as they work to develop cutting edge technology. The partnership between the UK Government and TMC demonstrates that international collaboration can drive both economic growth and improvement to quality of life.”

The 16 companies making up the inaugural cohort are as follows, according to TMC.

  • AINOSTICS aims to revolutionize the treatment and prevention of neurological conditions, such as dementia, by developing innovative AI-enabled solutions that draw novel insights from routinely acquired non-invasive medical scans to deliver accurate diagnosis and outcome prediction, and in turn facilitate personalized care and timely access to disease-modifying treatments for patients.
  • Alvie is a blended human plus AI-enabled digital solution providing personalised pre and rehabilitation coaching and supportive care for cancer and surgery. Alvie's technology combines data profiling, risk-stratification and tailored prescriptions of health and well-being with curated educational content, targeted behaviour change coaching and expert support through chat messaging and virtual consultations.
  • C the Signs™ is a validated AI cancer prediction platform, which can identify patients at risk of cancer at the earliest and most curable stage of the disease. Used by healthcare professionals, C the Signs can identify which tumor type a patient is at risk of and recommend the most appropriate next step in less than 30 seconds. The platform has detected over 10,000 patients with cancer, with over 50 different types of cancer diagnosed, and with a sensitivity of >98% for cancer.
  • At PEP Health, We believe all patients deserve the best care possible. Our cutting-edge machine-learning technology enables healthcare organisations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
  • PreciousMD improves the lives of lung-cancer and other lung-related illnesses patients worldwide by enabling imaging-based diagnostics needed for personalized treatment pathways.
  • Ufonia is an autonomous telemedicine company, we use large language models and voice AI to increase the capacity of clinical professionals.
  • My mhealth offers digital therapeutics for a range of long-term conditions- COPD, Asthma, Diabetes and Heart Disease. Our product has been successfully deployed in the UK and India, with >100,000 users registered to date. Our solutions empower patients to self-manage their conditions, resulting in dramatic improvements in outcomes, as evidenced through multiple clinical trials and real-world evaluations.
  • At Surgery Hero, we offer a clinically backed solution that ensures whole-human support before and after surgery. We help health systems, employers and health plans cut costs without sacrificing quality of care.
  • Panakeia's software platform enables extremely rapid multi-omics profiling in minutes directly from routinely used tissue images without needing wet lab assays.
  • QV Bioelectronics are striving to deliver longer, better quality lives for brain tumour patients. Using their first-of-its-kind implantable electric field therapy device, GRACE, QV will provide effective, focal & continuous treatment without impacting patient quality of life.
  • 52 North is a med-tech company focused on improving health outcomes and health equity by reinventing care pathways. The NeutroCheck® solution is a finger-prick blood test and digital platform built to significantly improve safety and quality of life for cancer patients, by helping to identify at-home those patients who are at risk of the most fatal side-effect of chemotherapy: neutropenic sepsis.
  • Somnus is fulfilling an unmet need in global healthcare by developing real-time, point of care blood propofol monitoring. Its products will improve the care of sedated and anaesthetised patients, save money for hospitals, and facilitate a major reduction in greenhouse gas emissions.
  • ScubaTx is a breakthrough organ transplant preservation company established to solve the global unmet need for cost-efficient and longer-duration organ preservation technology. ScubaTx has developed a simple, small and affordable device which uses Persufflation to extend the preservation of organs.
  • IBEX is on a mission to help people live active, healthy and productive lives by increasing their access to early diagnosis of osteoporosis. The IBEX BH software as medical device delvers routine, automated assessment of fracture risk from routine radiology for earlier detection and more equitable treatment of osteoporosis.
  • NuVision produces products derived from donated human amniotic membrane that are used in ophthalmology to help patients with chronic, traumatic and post-surgical wounds of the eye to be treated earlier and recover more fully and more quickly. The company’s products are also used in the management of dry eye disease, a debilitating conditions that affects around 17m people in the USA.
  • Calon Cardio-Technology is on a mission to improve quality of life for patients with Left Ventricular Assist devices (LVAD) and reduce the common post operative complications associated with these implantable heart pumps. We plan to do this by introducing a completely wireless heart pump system and augment patient follow-up with built-in remote monitoring capabilities.

Trending News